Publications

Detailed Information

Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin

DC Field Value Language
dc.contributor.authorAdachi, Yasushi-
dc.contributor.authorLi, Rong-
dc.contributor.authorYamamoto, Hiroyuki-
dc.contributor.authorMin, Yongfen-
dc.contributor.authorWang, Yu-
dc.contributor.authorLi, Hua-
dc.contributor.authorLee, Choon-Taek-
dc.contributor.authorCarbone, David P.-
dc.contributor.authorShinomura, Yasuhisa-
dc.contributor.authorImai, Kohzoh-
dc.contributor.authorArimura, Yoshiaki-
dc.contributor.authorImsumran, Arisa-
dc.contributor.authorPiao, Wenhua-
dc.date.accessioned2012-06-26T00:52:34Z-
dc.date.available2012-06-26T00:52:34Z-
dc.date.issued2009-08-
dc.identifier.citationCARCINOGENESIS; Vol.30 8; 1305-1313ko_KR
dc.identifier.issn0143-3334-
dc.identifier.urihttps://hdl.handle.net/10371/77415-
dc.description.abstractInsulin-like growth factor-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of gastrointestinal (GI) cancers. We have previously shown significant therapeutic activity for recombinant adenoviruses expressing dominant-negative insulin-like growth factor-I receptor (IGF-IR/dn), including suppression of tumor invasion. In this study, we sought to evaluate the mechanism of inhibition of invasion and the relationship between IGF-IR and matrix metalloproteinase (MMP) activity in GI carcinomas. We analyzed the role of IGF-IR on invasion in three GI cancer cell lines, colorectal adenocarcinoma, HT29; pancreatic adenocarcinoma, BxPC3 and gastric adenocarcinoma, MKN45, using a modified Boyden chamber method and subcutaneous xenografts in nude mice. The impact of IGF-IR signaling on the expression of MMPs and the effects of blockade of matrilysin or IGF-IR on invasiveness were assessed using recombinant adenoviruses, a tyrosine kinase inhibitor NVP-AEW541 and antisense matrilysin. Invasive subcutaneous tumors expressed several MMPs. IGF-IR/dn reduced the expression of these MMPs but especially matrilysin (MMP-7). Insulin-like growth factor (IGF) stimulated secretion of matrilysin and IGF-IR/dn blocked IGF-mediated matrilysin induction in three GI cancers. Both IGF-IR/dn and inhibition of matrilysin reduced in vitro invasion to the same degree. NVP-AEW541 also reduced cancer cell invasion both in vitro and in murine xenograft tumors via suppression of matrilysin. Thus, blockade of IGF-IR is involved in the suppression of cancer cell invasion through downregulation of matrilysin. Strategies of targeting IGF-IR may have significant therapeutic utility to prevent invasion and progression of human GI carcinomas.ko_KR
dc.language.isoenko_KR
dc.publisherOXFORD UNIV PRESSko_KR
dc.titleInsulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysinko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이춘택-
dc.identifier.doi10.1093/carcin/bgp134-
dc.citation.journaltitleCARCINOGENESIS-
dc.description.citedreferencePiao WH, 2008, MOL CANCER THER, V7, P1483, DOI 10.1158/1535-7163.MCT-07-2395-
dc.description.citedreferenceMiyamoto S, 2007, CANCER SCI, V98, P685-
dc.description.citedreferenceImsumran A, 2007, CARCINOGENESIS, V28, P947, DOI 10.1093/carcin/bgl247-
dc.description.citedreferenceMitsui Y, 2006, CANCER RES, V66, P9913, DOI 10.1158/0008-5472.CAN-06-0377-
dc.description.citedreferenceGirnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106-
dc.description.citedreferenceHarper J, 2006, CANCER RES, V66, P1940, DOI 10.1158/0008-5472.CAN-05-2036-
dc.description.citedreferenceADACHI Y, 2006, DIGEST ENDOSC, V18, P245-
dc.description.citedreferenceShimizu M, 2005, BIOCHEM BIOPH RES CO, V334, P947, DOI 10.1016/j.bbrc.2005.06.182-
dc.description.citedreferenceNakamura M, 2005, BIOCHEM BIOPH RES CO, V333, P1011, DOI 10.1016/j.bbrc.2005.06.010-
dc.description.citedreferenceMin Y, 2005, GUT, V54, P591, DOI 10.1136/gut.2004.048926-
dc.description.citedreferenceNosho K, 2005, BRIT J CANCER, V92, P1193, DOI 10.1038/sj.bjc.6602442-
dc.description.citedreferenceFoulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712-
dc.description.citedreferenceNosho K, 2004, CLIN CANCER RES, V10, P7950-
dc.description.citedreferenceGarcia-Echeverria C, 2004, CANCER CELL, V5, P231-
dc.description.citedreferenceMochizuki S, 2004, BIOCHEM BIOPH RES CO, V315, P79, DOI 10.1016/j.bbrc.2004.01.022-
dc.description.citedreferenceMiyamoto S, 2004, CANCER RES, V64, P665-
dc.description.citedreferenceBurtrum D, 2003, CANCER RES, V63, P8912-
dc.description.citedreferencePavelic K, 2003, J PATHOL, V201, P430, DOI 10.1002/path.1465-
dc.description.citedreferenceMin YF, 2003, CANCER RES, V63, P6432-
dc.description.citedreferenceZhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197-
dc.description.citedreferenceAdachi Y, 2002, GASTROENTEROLOGY, V123, P1191, DOI 10.1053/gast.2002.36023-
dc.description.citedreferenceAdachi Y, 2001, TUMOR BIOL, V22, P247-
dc.description.citedreferenceDunn SE, 2001, CANCER RES, V61, P1367-
dc.description.citedreferenceYu H, 2000, J NATL CANCER I, V92, P1472-
dc.description.citedreferenceAdachi Y, 1999, GUT, V45, P252-
dc.description.citedreferenceYamamoto H, 1999, CANCER RES, V59, P3313-
dc.description.citedreferenceFreier S, 1999, GUT, V44, P704-
dc.description.citedreferenceMa J, 1999, J NATL CANCER I, V91, P620-
dc.description.citedreferenceSimmons JG, 1999, AM J PHYSIOL-GASTR L, V276, pG817-
dc.description.citedreferenceMira E, 1999, ENDOCRINOLOGY, V140, P1657-
dc.description.citedreferenceYamamoto H, 1999, JPN J CLIN ONCOL, V29, P58-
dc.description.citedreferenceAdachi Y, 1998, INT J ONCOL, V13, P1031-
dc.description.citedreferenceLong L, 1998, CANCER RES, V58, P3243-
dc.description.citedreferenceYamamoto H, 1997, GASTROENTEROLOGY, V112, P1290-
dc.description.citedreferenceWilson CL, 1997, P NATL ACAD SCI USA, V94, P1402-
dc.description.citedreferenceStetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147-
dc.description.citedreferenceCrawford HC, 1996, ENZYME PROTEIN, V49, P20-
dc.description.citedreferenceBERGMANN U, 1995, CANCER RES, V55, P2007-
dc.description.citedreferenceYAMAMOTO H, 1995, INT J CANCER, V61, P218-
dc.description.citedreferenceBASERGA R, 1995, CANCER RES, V55, P249-
dc.description.citedreferenceBASERGA R, 1994, CELL, V79, P927-
dc.description.citedreferenceSELL C, 1993, P NATL ACAD SCI USA, V90, P11217-
dc.description.citedreferenceLIU JP, 1993, CELL, V75, P59-
dc.description.citedreferenceYOSHIMOTO M, 1993, INT J CANCER, V54, P614-
dc.description.citedreferenceREMACLEBONNET M, 1992, INT J CANCER, V52, P910-
dc.description.citedreferenceMIYAZAKI K, 1990, CANCER RES, V50, P7758-
dc.description.citedreferenceTHOMPSON MA, 1990, ENDOCRINOLOGY, V126, P3033-
dc.description.citedreferenceWOESSNER JF, 1988, J BIOL CHEM, V263, P16918-
dc.description.citedreferenceULLRICH A, 1986, EMBO J, V5, P2503-
dc.description.citedreferenceLIOTTA LA, 1986, CANCER RES, V46, P1-
dc.description.tc9-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share